IN2014MN01571A - - Google Patents
Info
- Publication number
- IN2014MN01571A IN2014MN01571A IN1571MUN2014A IN2014MN01571A IN 2014MN01571 A IN2014MN01571 A IN 2014MN01571A IN 1571MUN2014 A IN1571MUN2014 A IN 1571MUN2014A IN 2014MN01571 A IN2014MN01571 A IN 2014MN01571A
- Authority
- IN
- India
- Prior art keywords
- ocular
- steroid
- pharmaceutical composition
- composition
- umol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000003431 steroids Chemical class 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261597189P | 2012-02-10 | 2012-02-10 | |
PCT/US2013/025390 WO2013119988A1 (en) | 2012-02-10 | 2013-02-08 | Pharmaceutical compositions to reduce complications of ocular steroid |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01571A true IN2014MN01571A (da) | 2015-05-15 |
Family
ID=48948063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1571MUN2014 IN2014MN01571A (da) | 2012-02-10 | 2013-02-08 |
Country Status (19)
Country | Link |
---|---|
US (2) | US10058616B2 (da) |
EP (1) | EP2797601B1 (da) |
JP (1) | JP6231995B2 (da) |
KR (1) | KR102060210B1 (da) |
CN (2) | CN107260679B (da) |
AU (1) | AU2013216861B2 (da) |
BR (1) | BR112014018393B1 (da) |
CA (1) | CA2862055C (da) |
CY (1) | CY1120323T1 (da) |
DK (1) | DK2797601T3 (da) |
ES (1) | ES2673330T3 (da) |
HK (1) | HK1201723A1 (da) |
IN (1) | IN2014MN01571A (da) |
NZ (1) | NZ628124A (da) |
PT (1) | PT2797601T (da) |
RU (1) | RU2660585C2 (da) |
TR (1) | TR201808592T4 (da) |
TW (1) | TWI620578B (da) |
WO (1) | WO2013119988A1 (da) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111415822A (zh) * | 2020-03-05 | 2020-07-14 | 沈阳农业大学 | 一种洋葱碳/二氧化锰阵列电极及其制备方法和应用 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201913375YA (en) * | 2016-04-19 | 2020-02-27 | Univ Nanyang Tech | Subconjuctival depot forming formulations for ocular drug delivery |
EP3691654A4 (en) | 2017-09-25 | 2021-11-24 | Surface Pharmaceuticals, Inc. | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES |
US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
AU2018372185B2 (en) * | 2017-11-21 | 2024-05-16 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
JP7463306B2 (ja) * | 2018-07-09 | 2024-04-08 | タイワン リポソーム カンパニー リミテッド | 関節内ステロイドの合併症を軽減する方法 |
KR20210141448A (ko) | 2018-12-27 | 2021-11-23 | 서피스 아프샐믹스 인코포레이티드 | 안구 표면 질환을 치료하기 위한 안과용 약학 조성물 및 방법 |
RU2716429C1 (ru) * | 2019-05-29 | 2020-03-11 | федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения рецидивирующей эрозии роговицы различного генеза |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
SE9100342D0 (sv) | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroid esters |
IL103907A0 (en) * | 1992-11-27 | 1993-04-04 | Pharmos Corp | Ophthalmic compositions |
EP1599183A2 (en) * | 2002-11-26 | 2005-11-30 | Gilead Sciences, Inc. | Method of drug loading in liposomes by gradient |
ES2352087T3 (es) | 2003-02-04 | 2011-02-15 | Bracco Suisse Sa | Agentes de contraste para ultrasonido y procedimiento para la preparación de los mismos. |
EP1768657B1 (en) * | 2004-06-23 | 2008-08-13 | Sirion Therapeutics, Inc. | Methods and compositions for treating ophthalmic conditions with retinyl derivates |
US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
PL2322183T3 (pl) | 2006-06-01 | 2015-01-30 | Santen Sas | Wykorzystanie proleku do podawania doocznego, śródszklistkowego |
WO2007150046A2 (en) * | 2006-06-22 | 2007-12-27 | Sirion Therapeutics, Inc | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity |
US20080118500A1 (en) * | 2006-11-16 | 2008-05-22 | Taiwan Liposome Company | Sustained releasing composition via local injection for treating eye diseases |
JP5514098B2 (ja) * | 2008-02-29 | 2014-06-04 | 公益財団法人名古屋産業科学研究所 | 後眼部到達用リポソーム及び後眼部疾患用医薬組成物 |
CN101502485A (zh) * | 2009-03-20 | 2009-08-12 | 中国药科大学 | 地塞米松眼用纳米立方液晶制剂及其制备方法 |
CN101926769A (zh) | 2009-06-24 | 2010-12-29 | 天津金耀集团有限公司 | 地塞米松磷酸钠脂质体注射液 |
US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
SG184127A1 (en) * | 2010-03-19 | 2012-10-30 | Massachusetts Inst Technology | Lipid vesicle compositions and methods of use |
US20130217657A1 (en) * | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
-
2013
- 2013-02-08 EP EP13747021.7A patent/EP2797601B1/en active Active
- 2013-02-08 DK DK13747021.7T patent/DK2797601T3/da active
- 2013-02-08 WO PCT/US2013/025390 patent/WO2013119988A1/en active Application Filing
- 2013-02-08 RU RU2014132553A patent/RU2660585C2/ru active
- 2013-02-08 IN IN1571MUN2014 patent/IN2014MN01571A/en unknown
- 2013-02-08 US US14/377,211 patent/US10058616B2/en active Active
- 2013-02-08 TW TW102105245A patent/TWI620578B/zh active
- 2013-02-08 CN CN201710573136.5A patent/CN107260679B/zh active Active
- 2013-02-08 CN CN201380008147.9A patent/CN104125830B/zh active Active
- 2013-02-08 AU AU2013216861A patent/AU2013216861B2/en active Active
- 2013-02-08 BR BR112014018393-7A patent/BR112014018393B1/pt active IP Right Grant
- 2013-02-08 KR KR1020147022121A patent/KR102060210B1/ko active IP Right Grant
- 2013-02-08 ES ES13747021.7T patent/ES2673330T3/es active Active
- 2013-02-08 NZ NZ628124A patent/NZ628124A/en unknown
- 2013-02-08 JP JP2014556741A patent/JP6231995B2/ja active Active
- 2013-02-08 CA CA2862055A patent/CA2862055C/en active Active
- 2013-02-08 TR TR2018/08592T patent/TR201808592T4/tr unknown
- 2013-02-08 PT PT137470217T patent/PT2797601T/pt unknown
-
2015
- 2015-03-04 HK HK15102213.0A patent/HK1201723A1/xx unknown
-
2018
- 2018-03-06 US US15/913,466 patent/US10350294B2/en active Active
- 2018-06-11 CY CY20181100606T patent/CY1120323T1/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111415822A (zh) * | 2020-03-05 | 2020-07-14 | 沈阳农业大学 | 一种洋葱碳/二氧化锰阵列电极及其制备方法和应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01571A (da) | ||
WO2012021107A3 (en) | A liposomal formulation for ocular drug delivery | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
TN2013000293A1 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
BR112015022476A2 (pt) | composições de oxaliplatina de lipossoma para terapia de câncer | |
MY175305A (en) | Proliposomal testosterone formulations | |
EA201400392A1 (ru) | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb | |
IN2014DN00277A (da) | ||
WO2008070463A3 (en) | Endoxifen methods and compositions | |
MX361858B (es) | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. | |
PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
BR112015022415A2 (pt) | composições de cisplatina lipossômica para terapia contra câncer | |
HRP20151039T1 (hr) | Upotreba omega masnih kiselina za lijeäśenje bolesti | |
CU20130168A7 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
NZ702705A (en) | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | |
WO2013032643A3 (en) | Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells | |
WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same | |
PH12015501407A1 (en) | Topical opthalmological pharmaceutical composition containing regorafenib | |
MY182553A (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
WO2013043744A3 (en) | Tricyclic compounds useful as neurogenic and neuroprotective agents | |
BR112014001503A2 (pt) | composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele | |
EA201590982A1 (ru) | Новые соединения в качестве ингибиторов диацилглицерин ацилтрансферазы | |
AR059581A1 (es) | Procedimientos para el tratamiento de degeneracion macular y afecciones oculares relacionadas | |
WO2014073946A3 (es) | Uso de las betalaínas y sus derivados para preparar un medicamento para el tratamiento, prevención, regulación y control de hepatopatías, patologías con infiltrado inflamatorio, necrosis y para la modificación de depósitos de lípidos |